Fair is Fair; But Science is Science
This article was originally published in RPM Report
Executive Summary
Theravance’s proposed new indication for Vibativ is not the first drug to fail because of evolving regulatory standards. It may, however, have provoked the clearest and most formal articulation of FDA’s views on the limits of “fairness” regarding drug development commitments when it comes to approval decisions.